利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

197 条记录 (耗时 0.031 秒)

    Composition and method for parenteral administration of ibuprofen D, L-or L-Lysine salt
    27.
    发明公开
    Composition and method for parenteral administration of ibuprofen D, L-or L-Lysine salt 有权
    组合物和用于肠胃外给药的方法布洛芬-D，L-或L-赖氨酸盐

    公开(公告)号：EP1205181A3

    公开(公告)日：2002-08-21

    申请号：EP01126687.1

    申请日：2001-11-08

    申请人： Farmacon-IL, LLC

    发明人： Darko, Laszlo

    IPC分类号： A61K31/19

    CPC分类号： A61K9/0019 ,  A61K31/192 ,  A61K31/195 ,  A61K47/183

    摘要： Pharmaceutical compositions are disclosed suitable for parenteral administration having anti-inflammatory, analgesic, and anti-pyretic properties, which consist of a therapeutically effective amount of d,l or l-lysine salt of R,S or S-ibuprofen as active ingredient dissolved in sterile water to form a solution in the absence of an inert atmosphere and either substantially free or absolutely free of any excipient, organic solvent, buffer, acid, base, salt other than the active ingredient and capable of storage in the absence of an inert atmosphere. Also disclosed are methods employing the new compositions in the treatment of pain and inflammation, in reducing fever and in treating patent ductus arterious or intraventricular hemorrhage in prematurely born neonates.

    BENZAMIDE FORMULATION WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY
    30.
    发明公开
    BENZAMIDE FORMULATION WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY 有权
    组蛋白去乙酰化酶抑制剂活性BENZAMIDFORMULIERUNG

    公开(公告)号：EP1208086A1

    公开(公告)日：2002-05-29

    申请号：EP00956496.4

    申请日：2000-08-29

    申请人： SCHERING AKTIENGESELLSCHAFT

    发明人： ISHIBASHI, Masahiko ,  SAKABE, Masahiro ,  SAKAI, Ikuo ,  SUZUKI, Tsuneji ,  ANDO, Tomoyuki

    IPC分类号： C07D213/30 ,  C07D213/75 ,  C07D213/65 ,  A61K31/4406 ,  A61P35/00

    CPC分类号： C07D213/30 ,  C07D213/65 ,  C07D213/75

    摘要： There are provided pharmaceutical formulations with improved oral absorptivity and injections that contain, as active ingredients, high concentrations of benzamide derivatives and their pharmaceutically acceptable salts, which are useful as histone deacetylase inhibitors. A pharmaceutical solution is prepared by dissolving a benzamide derivative or a pharmaceutically acceptable salt thereof in an organic solvent and/or acidic liquid, and a pharmaceutical formulation is prepared by adding a surfactant, an acidic substance and/or a polyethylene glycol. The present invention has enabled dissolution of benzamide derivatives or their pharmaceutically acceptable salts at high concentrations, to prepare practical injections and oral liquid formulations and improve absorptivity with oral administration.